Y-mAbs Therapeutics, Inc. (YMAB) was a commercial-stage biopharmaceutical company focused on antibody-based and radiopharmaceutical cancer therapies. Company news centered on DANYELZA® (naxitamab-gqgk), an anti-GD2 therapy for relapsed or refractory high-risk neuroblastoma, and on clinical development of the SADA Pretargeted Radioimmunotherapy platform, including GD2-SADA and CD38-SADA programs.
Recurring updates also covered R&D presentations, NCCN guideline references, quarterly operating and financial results, material agreements, capital-structure disclosures and governance matters. Later corporate-status news covered the completed merger, Nasdaq listing changes and the company’s transition out of public-company reporting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.